FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887175626> ?p ?o ?g. }

• W2887175626 endingPage "B108" @default.
• W2887175626 startingPage "B108" @default.
• W2887175626 abstract "Abstract Necitumumab (Nmab) in combination with chemotherapy has demonstrated overall survival benefit in patients with advanced or metastatic squamous non-small cell lung cancer (SqNSCLC). The PI3K/ mTOR pathway shows aberrant activity in multiple tumor types and is implicated in the development of intrinsic and acquired resistance to anti-EGFR therapy. LY3023414, a potent dual PI3K/mTOR inhibitor, is currently undergoing clinical evaluation. The objective of this study was to evaluate the combination effects of Nmab and LY3023414 in multiple tumor models. Nmab and/or LY3023414 were evaluated using Cancer Cell Sensitivity Profiling (CCSP) using a panel of ~500 genetically and histologically diverse human tumor cell lines. The combination treatment showed greater inhibition of tumor cell growth as compared to single-agent treatments in a large fraction of the cell lines tested. The combination effect was further assessed in 21 patient-derived xenograft (PDX) models across multiple tumor types with and without genetic alterations in the PI3K pathway. Compared to both monotherapies, the combination treatment demonstrated greater efficacy in 16 of 21 models, and reached statistical significance in 6 models. Nmab -/+ LY3023414 was also evaluated in a panel of 40 SqNSCLC PDX models using a single-mouse trial format. Combination therapy exhibited significant benefit over either monotherapy as exemplified by disease control (61% for combination vs 17.5% and 34.3% for Nmab and LY3023414, respectively) and overall response rate (22% for combination vs 10% and 5.7% for Nmab and LY3023414, respectively). Median time to tumor doubling or event-free survival (mEFS) was also in favor of the combination therapy (mEFS = 38.9 days for combination vs 14.2 and 32.4 days for Nmab and LY3023414, respectively). To gain mechanistic insights into the combinatorial effect observed, we employed a high-content gene/protein expression assay (nCounter Vantage 3D RNA:Protein Solid Tumor Signaling Pathways Panel) in a SqNSCLC PDX model harboring PIK3CA mutation that was highly sensitive to the combination therapy. nCounter Vantage 3D analysis confirmed inhibition of the PI3K/mTOR pathway in LY3023414-treated tumors. A more robust effect on signaling events downstream of mTOR was observed in the combination group. Furthermore, pathway analysis of the gene expression data suggested alterations in cell cycle/apoptosis, DNA repair, Notch, TGFb, and Wnt signaling in the combination group. Collectively, these data indicate that the Nmab/LY3023414 combination provides a benefit over both monotherapies. A more profound blockade of the PI3K/ mTOR pathway accompanied by inhibition of tumor cell cycle, survival, and DNA repair mechanisms may underlie this effect. Citation Format: Maxine A. Melchior, Xuemei Guo, Gregory P. Donoho, Philip W. Iversen, Thompson N. Doman, Manisha Brahmachary, Xueqian Gong, Gerald E. Hall, Jason R. Manro, Yung-mae M. Yao, Sean Buchanan, Tod Smeal, Michael D. Kalos, Ruslan D. Novosiadly. Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B108." @default.
• W2887175626 created "2018-08-22" @default.
• W2887175626 creator A5000205895 @default.
• W2887175626 creator A5004738391 @default.
• W2887175626 creator A5006172629 @default.
• W2887175626 creator A5011965242 @default.
• W2887175626 creator A5013433702 @default.
• W2887175626 creator A5020198038 @default.
• W2887175626 creator A5022346083 @default.
• W2887175626 creator A5037720065 @default.
• W2887175626 creator A5037746795 @default.
• W2887175626 creator A5041068728 @default.
• W2887175626 creator A5051215714 @default.
• W2887175626 creator A5056382986 @default.
• W2887175626 creator A5071061160 @default.
• W2887175626 creator A5084679761 @default.
• W2887175626 date "2018-01-01" @default.
• W2887175626 modified "2023-09-27" @default.
• W2887175626 title "Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models" @default.
• W2887175626 doi "https://doi.org/10.1158/1535-7163.targ-17-b108" @default.
• W2887175626 hasPublicationYear "2018" @default.
• W2887175626 type Work @default.
• W2887175626 sameAs 2887175626 @default.
• W2887175626 citedByCount "0" @default.
• W2887175626 crossrefType "journal-article" @default.
• W2887175626 hasAuthorship W2887175626A5000205895 @default.
• W2887175626 hasAuthorship W2887175626A5004738391 @default.
• W2887175626 hasAuthorship W2887175626A5006172629 @default.
• W2887175626 hasAuthorship W2887175626A5011965242 @default.
• W2887175626 hasAuthorship W2887175626A5013433702 @default.
• W2887175626 hasAuthorship W2887175626A5020198038 @default.
• W2887175626 hasAuthorship W2887175626A5022346083 @default.
• W2887175626 hasAuthorship W2887175626A5037720065 @default.
• W2887175626 hasAuthorship W2887175626A5037746795 @default.
• W2887175626 hasAuthorship W2887175626A5041068728 @default.
• W2887175626 hasAuthorship W2887175626A5051215714 @default.
• W2887175626 hasAuthorship W2887175626A5056382986 @default.
• W2887175626 hasAuthorship W2887175626A5071061160 @default.
• W2887175626 hasAuthorship W2887175626A5084679761 @default.
• W2887175626 hasConcept C121608353 @default.
• W2887175626 hasConcept C126322002 @default.
• W2887175626 hasConcept C143998085 @default.
• W2887175626 hasConcept C183713625 @default.
• W2887175626 hasConcept C190283241 @default.
• W2887175626 hasConcept C2776256026 @default.
• W2887175626 hasConcept C2776999253 @default.
• W2887175626 hasConcept C502942594 @default.
• W2887175626 hasConcept C55493867 @default.
• W2887175626 hasConcept C71924100 @default.
• W2887175626 hasConcept C86554907 @default.
• W2887175626 hasConcept C86803240 @default.
• W2887175626 hasConcept C98274493 @default.
• W2887175626 hasConceptScore W2887175626C121608353 @default.
• W2887175626 hasConceptScore W2887175626C126322002 @default.
• W2887175626 hasConceptScore W2887175626C143998085 @default.
• W2887175626 hasConceptScore W2887175626C183713625 @default.
• W2887175626 hasConceptScore W2887175626C190283241 @default.
• W2887175626 hasConceptScore W2887175626C2776256026 @default.
• W2887175626 hasConceptScore W2887175626C2776999253 @default.
• W2887175626 hasConceptScore W2887175626C502942594 @default.
• W2887175626 hasConceptScore W2887175626C55493867 @default.
• W2887175626 hasConceptScore W2887175626C71924100 @default.
• W2887175626 hasConceptScore W2887175626C86554907 @default.
• W2887175626 hasConceptScore W2887175626C86803240 @default.
• W2887175626 hasConceptScore W2887175626C98274493 @default.
• W2887175626 hasIssue "1_Supplement" @default.
• W2887175626 hasLocation W28871756261 @default.
• W2887175626 hasOpenAccess W2887175626 @default.
• W2887175626 hasPrimaryLocation W28871756261 @default.
• W2887175626 hasRelatedWork W1967103478 @default.
• W2887175626 hasRelatedWork W1969312432 @default.
• W2887175626 hasRelatedWork W1997117033 @default.
• W2887175626 hasRelatedWork W2032912323 @default.
• W2887175626 hasRelatedWork W2063373438 @default.
• W2887175626 hasRelatedWork W2106062658 @default.
• W2887175626 hasRelatedWork W2332226957 @default.
• W2887175626 hasRelatedWork W2372561159 @default.
• W2887175626 hasRelatedWork W2375344515 @default.
• W2887175626 hasRelatedWork W2390152934 @default.
• W2887175626 hasVolume "17" @default.
• W2887175626 isParatext "false" @default.
• W2887175626 isRetracted "false" @default.
• W2887175626 magId "2887175626" @default.
• W2887175626 workType "article" @default.